共 27 条
- [21] Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomesJournal of Thrombosis and Thrombolysis, 2017, 44 : 442 - 447B. T. Samuelson BannowR. B. WalterT. B. GernsheimerD. A. Garcia
- [22] Therapy-Related Myeloid Neoplasms in Patients With Acute Promyelocytic Leukemia Treated With All-Trans-Retinoic Acid and Anthracycline-Based ChemotherapyJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (24) : 3872 - 3879Montesinos, PauGonzalez, Jose D.Gonzalez, JoseRayon, Chelode Lisa, ElenaAmigo, Maria L.Ossenkoppele, Gert J.Penarrubia, Maria J.Perez-Encinas, ManuelBergua, JuanDeben, GuillermoSayas, Maria J.de la Serna, JavierRibera, Josep M.Bueno, JavierMilone, GustavoRivas, ConchaBrunet, SalutLowenberg, BobSanz, Miguel
- [23] The Impact of Smoking on Relapse and Survival in Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with the Combination of Intensive Therapy with Tyrosine Kinase InhibitorCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S180 - S180Sasaki, KojiKantarjian, HagopRichard-Carpentier, GuillaumeRavandi, FarhadShort, NicholasGarcia-Manero, GuillermoDaver, NavalKadia, TapanKonopleva, MarinaJain, NitinIssa, GhayasEstrov, ZeevGarris, RebeccaKhouri, MariaNasnas, PatricePemmaraju, NaveenCortes, JorgeO'Brien, SusanJabbour, Elias
- [24] KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL): Outcomes in Patients Who Were Treated with Prior Blinatumomab in ZUMA-3CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S184 - S184Shah, Bijal D.Oluwole, Olalekan O.Baer, Maria R.Bishop, Michael R.Holmes, HoustonSchiller, Gary J.Donnellan, WilliamO'Dwyer, Kristen M.Mardiros, ArmenRossi, John M.Shen, TongXue, AllenJain, Rajul K.Vezan, RemusWierda, William G.
- [25] Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia - A 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01CANCER, 2001, 92 (01) : 15 - 22Waber, DPShapiro, BLCarpentieri, SCGelber, RDZou, GYDufresne, ARomero, ITarbell, NJSilverman, LBSallan, SE
- [26] Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0–45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocolBMC Cancer, 22Linea Natalie ToksvangBodil Als-NielsenChristopher BaconRuta BertasiuteXimo DuarteGabriele EscherichElín Anna HelgadottirInga Rinvoll JohannsdottirÓlafur G. JónssonPiotr KozlowskiCecilia LangenskjöldKristi LepikRiitta NiinimäkiUlrik Malthe OvergaardMari PunabRiikka RätyHeidi SegersInge van der SluisOwen Patrick SmithMarion StrulluGoda VaitkevičienėHilde Skuterud WikMats HeymanKjeld Schmiegelow
- [27] Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocolBMC CANCER, 2022, 22 (01)Toksvang, Linea NatalieAls-Nielsen, BodilBacon, ChristopherBertasiute, RutaDuarte, XimoEscherich, GabrieleHelgadottir, Elin AnnaJohannsdottir, Inga RinvollJonsson, Olafur G.Kozlowski, PiotrLangenskjold, CeciliaLepik, KristiNiinimaki, RiittaOvergaard, Ulrik MalthePunab, MariRaty, RiikkaSegers, Heidivan der Sluis, IngeSmith, Owen PatrickStrullu, MarionVaitkeviciene, GodaWik, Hilde SkuterudHeyman, MatsSchmiegelow, Kjeld